Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers


1. 2728667-27-2
2. N-(1-(8-((3-methyl-4-((1-methyl-1h-benzo[d]imidazol-5-yl)oxy)phenyl)amino)pyrimido[5,4-d]pyrimidin-2-yl)piperidin-4-yl)acrylamide
3. Bi1810631
4. Bi-1810631
5. N-[1-[4-[3-methyl-4-(1-methylbenzimidazol-5-yl)oxyanilino]pyrimido[5,4-d]pyrimidin-6-yl]piperidin-4-yl]prop-2-enamide
6. Zongertinib?
7. Zongertinib [inn]
8. Drh7r67uvl
9. Zongertinib [usan]
10. Zongertinib (jan/usan/inn)
11. Chembl5314498
12. Schembl23957509
13. Gtpl12387
14. Wlz3778
15. Glxc-27939
16. Ex-a8033
17. Nsc854531
18. Nsc-854531
19. Da-59312
20. Ts-09568
21. Example I-01 [wo2021213800a1]
22. Hy-148810
23. Cs-0641245
24. D12879
25. G65208
26. 2-propenamide, N-[1-[8-[[3-methyl-4-[(1-methyl-1h-benzimidazol-5-yl)oxy]phenyl]amino]pyrimido[5,4-d]pyrimidin-2-yl]-4-piperidinyl]-
27. N-[1-(8-{3-methyl-4-[(1-methyl-1h-1,3-benzimidazol-5- Yl)oxy]anilino}pyrimido[5,4-d]pyrimidin-2-yl)piperidin-4- Yl]prop-2-enamide
| Molecular Weight | 535.6 g/mol |
|---|---|
| Molecular Formula | C29H29N9O2 |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 123 |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 870 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
NDC Package Code : 12714-301
Start Marketing Date : 2025-09-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 43076-031
Start Marketing Date : 2025-08-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 50909-1914
Start Marketing Date : 2025-08-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC Package Code : 12714-301
Start Marketing Date : 2025-09-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 43076-031
Start Marketing Date : 2025-08-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 50909-1914
Start Marketing Date : 2025-08-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (50kg/100kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The collaboration aims to advance Zongertinib for ERBB2 in HER2-positive breast cancer.
Lead Product(s): Zongertinib,Zanidatamab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Jazz Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Zanidatamab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Jazz Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Boehringer Ingelheim, Jazz Pharma collaborate on HER2 therapy in breast cancer
Details : The collaboration aims to advance Zongertinib for ERBB2 in HER2-positive breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zongertinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Zongertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 29, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zongertinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hernexeos (zongertinib) is a ERBB2 blocker indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer.
Lead Product(s): Zongertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Hernexeos
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer’s Hernexeos Approved in China as First Oral Targeted Therapy
Details : Hernexeos (zongertinib) is a ERBB2 blocker indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer.
Product Name : Hernexeos
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hernexeos (zongertinib) is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic non-squamous NSCLC whose tumors have ERBB2 tyrosine kinase mutations.
Lead Product(s): Zongertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Hernexeos
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Accelerated Nod To HERNEXEOS As First Oral HER2+ NSCLC Therapy
Details : Hernexeos (zongertinib) is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic non-squamous NSCLC whose tumors have ERBB2 tyrosine kinase mutations.
Product Name : Hernexeos
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.
Lead Product(s): Zongertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zongertinib Receives Priority Review for HER2 (ERBB2)-mutant Advanced NSCLC
Details : BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Diseases.
Lead Product(s): Zongertinib,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
Details : Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.
Lead Product(s): Zongertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer’s Zongertinib Shows Efficacy in HER2 Mutated Lung Cancer Patients
Details : BI 1810631 (zongertinib) is an investigational oral HER2 tyrosine kinase inhibitor (TKI) in development being investigated in patients with advanced NSCLC with activating HER2 mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): Zongertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Zongertinib,Dabigatran Etexilate Mesylate,Rosuvastatin Calcium,Metformin,Furosemide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Dabigatran Etexilate Mesylate,Rosuvastatin Calcium,Metformin,Furosemide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Zongertinib,Midazolam,Omeprazole,Repaglinide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Midazolam,Omeprazole,Repaglinide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patents & EXCLUSIVITIES
ABOUT THIS PAGE
17
PharmaCompass offers a list of Zongertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zongertinib manufacturer or Zongertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zongertinib manufacturer or Zongertinib supplier.
PharmaCompass also assists you with knowing the Zongertinib API Price utilized in the formulation of products. Zongertinib API Price is not always fixed or binding as the Zongertinib Price is obtained through a variety of data sources. The Zongertinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 2728667-27-2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 2728667-27-2, including repackagers and relabelers. The FDA regulates 2728667-27-2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 2728667-27-2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 2728667-27-2 supplier is an individual or a company that provides 2728667-27-2 active pharmaceutical ingredient (API) or 2728667-27-2 finished formulations upon request. The 2728667-27-2 suppliers may include 2728667-27-2 API manufacturers, exporters, distributors and traders.
click here to find a list of 2728667-27-2 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 2728667-27-2 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 2728667-27-2 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 2728667-27-2 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 2728667-27-2 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 2728667-27-2 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 2728667-27-2 suppliers with NDC on PharmaCompass.
2728667-27-2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 2728667-27-2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 2728667-27-2 GMP manufacturer or 2728667-27-2 GMP API supplier for your needs.
A 2728667-27-2 CoA (Certificate of Analysis) is a formal document that attests to 2728667-27-2's compliance with 2728667-27-2 specifications and serves as a tool for batch-level quality control.
2728667-27-2 CoA mostly includes findings from lab analyses of a specific batch. For each 2728667-27-2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
2728667-27-2 may be tested according to a variety of international standards, such as European Pharmacopoeia (2728667-27-2 EP), 2728667-27-2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (2728667-27-2 USP).